Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Clinical Trials, Lymphoid Leukemias, ALL, Hodgkin Lymphoma, Biological, Lymphomas, Non-Hodgkin Lymphoma, Clinical Research, B Cell Lymphoma, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Clinically Relevant, Diseases, Aggressive Lymphoma, Therapies, Lymphoid Malignancies
Type: Oral
Hematology Disease Topics & Pathways:
Clinical Trials, Lymphoid Leukemias, ALL, Hodgkin Lymphoma, Biological, Lymphomas, Non-Hodgkin Lymphoma, Clinical Research, B Cell Lymphoma, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Clinically Relevant, Diseases, Aggressive Lymphoma, Therapies, Lymphoid Malignancies
Sunday, December 12, 2021: 12:00 PM-1:30 PM
B401-B402, Level 4, Building B
(Georgia World Congress Center)
Moderators:
Saar Gill, MD, PhD, University of Pennsylvania
and
Martina Pennisi, MD, Fondazione IRCCS Istituto Nazionale dei Tumori
Disclosures:
Gill: Novartis: Other: licensed intellectual property, Research Funding; Carisma Therapeutics: Current holder of stock options in a privately-held company, Research Funding; Interius Biotherapeutics: Current holder of stock options in a privately-held company, Research Funding. Pennisi: Gilead Sciences: Consultancy.
12:00 PM
12:30 PM
12:45 PM
1:00 PM
1:15 PM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH